The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
: Aspi-Cor, Aspir-Low, Aspir 81, Bufferin, Bayer Plus, Ecpirin, Durlaza, Ecotrin, Vazalore, Miniprin
Synonyms :
aspirin
Class :
Antiplatelet Agents, Hematologic; NSAIDs; Salicylates, Platelet aggregation inhibitors
Brand Name :
: Aspi-Cor, Aspir-Low, Aspir 81, Bufferin, Bayer Plus, Ecpirin, Durlaza, Ecotrin, Vazalore, Miniprin
Synonyms :
aspirin
Class :
Antiplatelet Agents, Hematologic; NSAIDs; Salicylates, Platelet aggregation inhibitors
Adult dosing
Dosage Forms & Strengths Â
Tablet
81, 325, 500 mg
Tablet-delayed release
162, 325, 500 mg
Tablet-chewable
81mg
Tablet-enteric coated
81, 162, 325, 650mg
capsule, liquid filled
81, 325 mg
ER-capsule
162.5 mg
Initial dose: 325 mg-1 g every 4 hours 10 days as needed
Maximum dose: 4 g once a day
Do not exceed the dose of 4 gm a day
3
g
Orally 
in divided doses as needed
3
g
oraly
in divided doses as needed
IR: 50-325 mg orally daily
ER: 162.5 mg orally daily
Prophylaxis
IR: 50-325 mg orally daily
ER: 162.5 mg orally daily
IR: 75-325 mg orally daily
ER: 162 mg orally daily
Prophylaxis
IR: 75-325 mg orally daily
ER: 162 mg orally daily
4 g orally daily in divided doses as needed
Systemic Lupus Erythematosus (SLE)
3 g orally in divided doses as needed
Age: >50 years
75-100 mg orally daily
prophylaxis:
75 mg to 162 mg once a day orally
Dosage Forms & Strengths Â
Tablet
81, 325, 500 mg
Tablet-delayed release
162, 325, 500 mg
Tablet-chewable
81mg
Tablet-enteric coated
81, 162, 325, 650mg
capsule, liquid filled
81, 325 mg
ER-capsule
162.5 mg
Weight: <50 kg: 10-15 mg/kg orally every 4 times a day; maybe increase up to 60-80 mg/kg
Weight: ≥50 kg: 325-650 mg orally every 4 times a day; do not exceed 4 g a day
Weight: <25 kg: 60-100 mg/kg orally in divided doses as needed
Weight: ≥25 kg: 2.4-3.6 g orally a day
Initial: 80-100 mg/kg orally in divided doses 14 days
Maintenance: 3-6 mg/kg orally as a single dose daily
75 mg to 100 mg once a day orally
choline magnesium trisalicylate
NSAIDs may enhance the adverse/toxic effect of Salicylates
may enhance the anticoagulant effect of Vitamin K Antagonists
may enhance the anticoagulant effect of Vitamin K Antagonists
may enhance the anticoagulant effect of Vitamin K Antagonists
may enhance the anticoagulant effect of Vitamin K Antagonists
may enhance the anticoagulant effect of Vitamin K Antagonists
may have an increased antiplatelet effect when combined with abrocitinib
may have an increasingly adverse effect when combined with apixaban
may have an increasingly adverse effect when combined with edoxaban
aspirin: they may increase the toxic effect of nonsteroidal anti-inflammatory agents
aspirin: they may increase the toxic effect of nonsteroidal anti-inflammatory agents
aspirin: they may increase the toxic effect of nonsteroidal anti-inflammatory agents
aspirin: they may increase the toxic effect of nonsteroidal anti-inflammatory agents
aspirin: they may increase the toxic effect of nonsteroidal anti-inflammatory agents
it may enhance the adverse/toxic effect of apixaban
NSAIDs may enhance the anticoagulant effect of Heparin
NSAIDs may enhance the anticoagulant effect of Heparin
NSAIDs may increase the serum concentration of Lithium
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
may increase the antiplatelet effect
may increase the anticoagulant effect of antiplatelet agents
may diminish the serum concentration when combined with aspirin
may have an increased anticoagulant effect when combined with Heparin
morphine (Systemic): they may decrease the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors)
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
CNS stimulants: they may increase the CNS stimulant effect of non-opioid drugs
use of sibutramine with aspirin can rise the risk of bleeding
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
when both the drugs are combined, there might be an increase in the anticoagulant effect
may have an increasingly adverse effect when combined with dexibuprofen
may decrease the diagnostic effect when combined with macimorelin
may have an increasingly adverse effect when combined with omacetaxine
probenecid's uricosuric effect is lessened by aspirin
It may increase pemetrexed toxicities by increasing the serum concentration. Avoid aspirin from the 2 days before, through the treatment, and after 2 days.
antiplatelet Properties may enhance the antiplatelet effect of abrocitinib
acemetacin may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
Ketorolac may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
antiplatelet agents increase the antiplatelet effect of abrocitinib
may have an increasingly adverse effect when combined with aspirin.
ketorolac intranasal: they may increase the toxic effect of aspirin
tenoxicam: they may increase the anticoagulant effect of Antiplatelet agents
probenecid: they may increase the anticoagulant effect of Antiplatelet agents
it May diminish the therapeutic effect of Loop Diuretics
it May diminish the therapeutic effect of Loop Diuretics
it May diminish the therapeutic effect of Loop Diuretics
NSAIDS may enhance the neuroexcitatory and/or seizure-potentiating effect of quinolones
NSAIDS may enhance the neuroexcitatory and/or seizure-potentiating effect of quinolones
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
NSAIDs may diminish the antihypertensive effect of Beta-Blockers
NSAIDs may diminish the antihypertensive effect of Beta-Blockers
NSAIDs may diminish the antihypertensive effect of Beta-Blockers
NSAIDs may diminish the antihypertensive effect of Beta-Blockers
NSAIDs may diminish the antihypertensive effect of Beta-Blockers
NSAIDs may enhance the adverse/toxic effect of Bisphosphonate Derivatives
NSAIDs may enhance the adverse/toxic effect of Bisphosphonate Derivatives
NSAIDs may enhance the adverse/toxic effect of Bisphosphonate Derivatives
NSAIDs may enhance the adverse/toxic effect of Bisphosphonate Derivatives
corticosteroids may enhance the adverse/toxic effect of NSAIDs
corticosteroids may enhance the adverse/toxic effect of NSAIDs
corticosteroids may enhance the adverse/toxic effect of NSAIDs
corticosteroids may enhance the adverse/toxic effect of NSAIDs
corticosteroids may enhance the adverse/toxic effect of NSAIDs
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
NSAIDsmay diminish the antihypertensive effect of Potassium-Sparing Diuretics
NSAIDsmay diminish the antihypertensive effect of Potassium-Sparing Diuretics
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
ACE Inhibitors may enhance the adverse/toxic effect of NSAIDs
ACE Inhibitors may enhance the adverse/toxic effect of NSAIDs
ACE Inhibitors may enhance the adverse/toxic effect of NSAIDs
ACE Inhibitors may enhance the adverse/toxic effect of NSAIDs
ACE Inhibitors may enhance the adverse/toxic effect of NSAIDs
antiplatelet agents may enhance the anticoagulant effect of thrombolytic Agents
choline magnesium trisalicylate
may enhance the adverse/toxic effect of salicylates
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may enhance the anticoagulant effect of thrombolytic agents
choline magnesium trisalicylate
may increase the risk of adverse effect of salicylates
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may increase the antiplatelet effect of other antiplatelet agents
may increase the antiplatelet effect of other antiplatelet agents
may have an increased anticoagulant effect when combined with Anticoagulants
may have an increased anticoagulant effect when combined with Anticoagulants
may have an increased antiplatelet effect when combined with Aspirin
may have an increased antiplatelet effect when combined with Aspirin
may have an increased antiplatelet effect when combined with Aspirin
may have an increased antiplatelet effect when combined with Aspirin
may have an increased antiplatelet effect when combined with Aspirin
choline magnesium trisalicylate
may have an increasingly adverse effect when combined with salicylates
may increase the anticoagulant effect of heparin
may increase the anticoagulant effect of heparin
may increase the anticoagulant effect of heparin
It may enhance the risk of bleeding by affecting coagulation when combined with omega-3 carboxylic acids
may increase the anticoagulation when combined with ginkgo biloba
It may enhance the risk of adverse effects when combined with Nonopiods
both forskolin and aspirin enhance anticoagulation
nafcillin and asprin, both either increase the levels of others by plasma protein binding or by decreasing renal clearance.
it increases the gastric pH, thereby decreasing the effect or level of neratinib
lansoprazole amoxicillin and clarithromycin
when amoxicillin combines with aspirin it decreases the effects of action of drug by plasma binding protein and results in lowering of renal clearance
amoxicillin and clavulanate potassium
when amoxicillin combines with aspirin it decreases the effects of action of drug by plasma binding protein and results in lowering of renal clearance
omeprazole amoxicillin and clarithromycin
when both drugs are combined, there may be a decreased effect of the drug's action by decreasing renal clearance
when both drugs are combined, there may be a decreased effect of the drug's action by decreasing renal clearance
when both drugs are combined, there may be an increased effect of other antiplatelet agents
it may increase the antiplatelet effect of properties of antiplatelet drugs
it may increase the antiplatelet effect of other antiplatelets agents
it may increase the effect of serotonergic agents
Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of aliskiren
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
bile Acid Sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents
antiplatelet agents may enhance the adverse/toxic effect of ibritumomab tiuxetan
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
it may enhance the antiplatelet effect of Agents with antiplatelet Properties
may diminish the therapeutic effect of angiotensin II Receptor Blockers
choline magnesium trisalicylate
may enhance the adverse/toxic effect of salicylates
NSAIDs may enhance the adverse/toxic effect of metformin
may decrease the levels of serum potassium
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may enhance the toxicity of the other through anti coagulation
may increase the antiplatelet effect of prostacyclin analogs
may increase the anti-platelet effect
may enhance the effect of antiplatelet properties
may increase the anti-coagulant action of anti-coagulants
may increase the antiplatelet effect of antiplatelet agents
may enhance the effect of other antiplatelet properties
may enhance the effect of other antiplatelet properties
may increase the antiplatelet effect of antiplatelet agents
may increase the antiplatelet effect of other antiplatelet agents
may increase the antiplatelet effect of other antiplatelet agents
may have an increasingly adverse effect when combined with Apixaban
may have an increasingly adverse effect when combined with Cephalothin
May have an increased anticoagulant effect when combined with Antiplatelet agents
may have an increasingly adverse effect when combined with Deoxycholic Acid
may have an increasingly adverse effect when combined with Edoxaban
May have an increasingly adverse effect when combined with Antiplatelet agents
May have an increased antiplatelet effect when combined with Antiplatelet agents
may have an increasingly adverse effect when combined with alendronate
may increase the toxic effect of salicylates
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may have an increased antiplatelet effect when combined with antiplatelet agents
may have an increased antiplatelet effect when combined with antiplatelet agents
may have an increased antiplatelet effect when combined with antiplatelet agents
may have an increased adverse effect when combined with ibritumomab tiuxetan
other antiplatelet agents increase the effect of anticoagulating agents
other antiplatelet agents increase the effect of anticoagulating agents
other antiplatelet agents increase the effect of anticoagulating agents
other antiplatelet agents increase the effect of anticoagulating agents
other antiplatelet agents increase the effect of anticoagulating agents
it increases the effect of antiplatelet agents
antiplatelet agents increase the effect of thrombolytic agents
choline magnesium trisalicylate
antiplatelet agents increase the toxicity of salicylates
it increases the effect of antiplatelet agents
antiplatelet agents increase the toxicity of obinutuzumab
they increase the efficacy of antiplatelet agents
it increases the efficacy of antiplatelet agents
may increase the anti-coagulant effect of Anti-coagulants
may increase the anticoagulant effect of Anticoagulants
may increase the adverse effect of pentosan polysulfate sodium
may increase the antiplatelet effect
it increases the effect of antiplatelet agents
other antiplatelet agents increase the anticoagulative effect of rivaroxaban
anagrelide: they may increase the antiplatelet effect of antiplatelet agents
lipid emulsion (plant oil-based)Â
lipid emulsion: they may increase the toxic effect of antiplatelet agents
pirtobrutinib: they may increase the antiplatelet effect of antiplatelet agents
prostaglandin: they may increase the antiplatelet effect of antiplatelet agents
prostaglandin: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K: they may increase the antiplatelet effect of antiplatelet agents
Vitamin D analogs: they may increase the antiplatelet effect of antiplatelet agents
Vitamin B12: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K antagonists: they may increase the antiplatelet effect of antiplatelet agents
Bile Acid Sequestrants: they may diminish the absorption of Antiplatelet Agent
dasabuvir: they may increase the anticoagulant effect antiplatelet agents
naftazone : they may increase the antiplatelet effect of antiplatelet agents
porfimer: they may increase the toxic effect of antiplatelet agents
verteporfin: they may increase the antiplatelet effect of Agents with antiplatelet agentss
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
may have an increasingly adverse effect when combined with opioid agonists
ramosetron: they may increase the antiplatelet effect of Agents with antiplatelet properties
topiramate: they may increase the antiplatelet effect of Agents with antiplatelet properties
zuclopenthixol: they may increase the antiplatelet effect of Agents with antiplatelet properties
etravirine: they may increase the antiplatelet effect of Agents with antiplatelet agent
alizapride: they may increase the antiplatelet effect of Agents with antiplatelet agent
piperacillin increases the effectiveness of aspirin by protein binding competition.
cefprozil increases the serum concentration of other drugs by reducing renal clearance
cefaclor increases the serum concentration of other drugs by reducing renal clearance
cefepime increases the serum concentration of other drugs by reducing renal clearance
cefuroxime increases the serum concentration of other drugs by reducing renal clearance
both, when used simultaneously, increases the effect on other through a synergistic activity
may intensify the negative/harmful impact of caplacizumab
by altering gastrointestinal absorption, the concentration of cyanocobalamin may be reduced with aspirin
Action:
Aspirin works by blocking the activity of COX enzymes that are involved in the production of prostaglandins; hence, it decreases the production of these hormones thus alleviating inflammation, pain and fever.
Frequency Not Defined Â
Hepatotoxicity
Hearing loss
CNS alteration
Angioedema
Pulmonary edema
Inhibition of Platelet aggregation
Bronchospasm
Dermatologic problems
Nausea
Tinnitus
Urticaria
Premature hemolysis
Rash
Renal damage
Contraindications:
Allergy to Aspirin or NSAIDs
Peptic Ulcer Disease
Bleeding Disorders
Children and Adolescents with Viral Infections
Asthma with Sensitivity to NSAIDs
Pregnancy
Cautions:
History of Gastrointestinal Bleeding
Concurrent Anticoagulant Therapy
Alcohol Use
Renal impairment
Pregnancy warnings:Â Â
AU TGA pregnancy category: C
US FDA pregnancy category: Not Assigned
Lactation: Excreted into human milk is known
Pregnancy Categories:Â Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Aspirin, a chemical name for acetylsalicylic acid is a common medication that possesses multiple therapeutic properties mainly attributed as anti-inflammatory, antipyretic, and antiplatelet agent.
Pharmacodynamics:
Cyclooxygenase (COX) Inhibition: Aspirin has been identified to have the ability of inhibiting the cyclooxygenase enzymes which are, the COX-1 and the COX-2 enzymes. These enzymes take part in conversion of arachidonic acid to prostaglandins that has role in inflammation, pain and fever.
Aspirin inhibits the functioning of the COX enzymes that are responsible for the synthesis of prostaglandins; therefore, this drug reduces the formation of these hormones to relieve inflammation, pain and fever.
Pharmacokinetics:
Absorption
It is rapidly absorbed in the stomach and small intestine. The bioavailability of aspirin is about 80-100%.
Distribution
The volume of distribution of aspirin is 170 mL/kg.
Aspirin primarily bound to plasma proteins albumin in the blood.
Aspirin could get absorbed in different tissues.
Metabolism
The drug is metabolised through esterase’s to salicylic acid which is the active ingredient.
Individuals with heavy liver ailments may be advice not to take salicylic acid as it is metabolized extensively in the liver; primordially converted to salicyluric acid through conjugation reactions with glycine and in the lesser extent with glucuronic acid.
Excretion and Elimination
Aspirin and its metabolites are cleared primarily by the kidneys.
Besides the filtration rate is depended on the pH of urine. The ion trapping mechanism enhances excretion in the urine because of the relatively alkaline pH of urine.
Higher dose has the half-life ranging from 15 to 30 hours and the lower dose is about 2 to 3 hours.
The drug is taken orally.
Patient Information Leaflet Â
Generic Name: aspirin
Why do we use aspirin?Â
Aspirin is a Platelet aggregation inhibitor, Salicylates, and NSAIDs. It is used to treat pain, fever, inflammation, heart attacks, strokes, and angina pectoris.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
